The repositioned drugs disulfiram/diethyldithiocarbamate combined to benznidazole: Searching for Chagas disease selective therapy, preventing toxicity and drug resistance

Juliana Almeida-Silva¹, Diego Silva Menezes², Juan Mateus Pereira Fernandes¹, Márcio Cerqueira Almeida⁷, Deyvison Rhuan Vasco-dos-Santos¹, Roberto Magalhães Saraiva³, Alessandra Lifsitch Viçosa⁴, Sandra Aurora Chavez Perez⁵, Sônia Gumes Andrade⁶, Ana Márcia Suarez-Fontes¹ and Marcos André Vannier-Santos¹*

Chagas disease (CD) affects at least 6 million people in 21 South American countries besides several thousand in other nations all over the world. It is estimated that at least 14,000 people die every year of CD. Since vaccines are not available, chemotherapy remains of pivotal relevance. About 30% of the treated patients cannot complete the therapy because of severe adverse reactions. Thus, the search for novel drugs is required. Here we tested the benznidazole (BZ) combination with the repositioned drugs disulfiram (DSF) and its derivative diethyldithiocarbamate (DETC) upon Trypanosoma cruzi in vitro and in vivo. DETC-BZ combination was synergistic diminishing epimastigote proliferation and enhancing selective indexes up to over 10-fold. DETC was effective upon amastigotes of the BZ- partially resistant Y and the BZ-resistant Colombiana strains. The combination reduced proliferation even using low concentrations (e.g., 2.5 µM). Scanning electron microscopy revealed membrane discontinuities and cell body volume reduction. Transmission electron microscopy revealed remarkable enlargement of endoplasmic reticulum cisternae besides, dilated mitochondria with decreased electron density and disorganized kinetoplast DNA. At advanced stages, the cytoplasm...
vacuolation apparently impaired compartmentation. The fluorescent probe H2-DCFDA indicates the increased production of reactive oxygen species associated with enhanced lipid peroxidation in parasites incubated with DETC. The biochemical measurement indicates the downmodulation of thiol expression. DETC inhibited superoxide dismutase activity on parasites was more pronounced than in infected mice. In order to approach the DETC effects on intracellular infection, peritoneal macrophages were infected with Colombiana trypomastigotes. DETC addition diminished parasite numbers and the DETC-BZ combination was effective, despite the low concentrations used. In the murine infection, the combination significantly enhanced animal survival, decreasing parasitemia over BZ. Histopathology revealed that low doses of BZ-treated animals presented myocardial amastigote, not observed in combination-treated animals. The picrosirius collagen staining showed reduced myocardial fibrosis. Aminotransferase aspartate, Aminotransferase de alanine, Creatine kinase, and urea plasma levels demonstrated that the combination was non-toxic. As DSF and DETC can reduce the toxicity of other drugs and resistance phenotypes, such a combination may be safe and effective.

**KEYWORDS**
Trypanosoma cruzi, disulfiram, drug combination, repositioning, Chagas disease, chemotherapy, Diethylidithiocarbamate

**Introduction**

At least 6-7 million people have Chagas disease (CD), mostly in Latin America (WHO - World Health Organization, 2021), where over 10% of the population is at risk of infection (Pérez-Molina and Molina, 2018). There are at least 4.6 million infected people in Brazil, which can reach 1.5% of the Brazilian population. In addition, about 70 million are at risk of infection by Trypanosoma cruzi (Dias et al., 2016). The parasitosis, also known as American trypanosomiasis, is already considered a public health problem on a global scale (Franco-Paredes et al., 2009; Coura and Viñas, 2010; Parker and Sethi, 2011).

CD causes economic losses in excess of US$1.2 billion/year to endemic countries in South America, in addition to more than $7 billion/year at global levels (Lee et al., 2013), including treatment and loss of productivity, not including the losses caused by infections by tourists and emigrants to North America, Europe, and Asia (COURA and Viñas, 2010) coming from South and Central America. Therefore, it can be inferred that effective drugs, besides promoting the quality of life of patients and their families, can provide considerable socioeconomic benefit.

Since CD discovery by the Brazilian researcher Carlos Chagas over a century ago, the disease is intensely studied, but only two drugs, benznidazole (BZ) and nifurtimox (NFX), are employed in CD treatment. However, BZ side effects lead to therapy discontinuation from approximately 30% of the cases up to eventually reaching 50% of the patients (Guggenbühl Noller et al., 2020). The option is NFX but a recent study (Crespillo-Andújar et al., 2018) reported that the use of NFX in patients who had been discontinued from BZ treatment still led to more than 12% of elevated toxicity, forcing physicians to permanently discontinue treatment. Therefore, there is pressing demand for the development of new drugs or therapeutic regimens for CD.

Different chemotherapy targets have been approached during the last decades (Duschak, 2011; Duschak, 2016; Beltran-Hortelano et al., 2017; Duschak, 2019; Beltran-Hortelano et al., 2022), and much was learned about the biochemistry and cell biology of T. cruzi, but new agents are still not in clinical use. Drug combinations may be promising for allowing dosing reduction (Bustamante et al., 2014), hampering resistance selection (Hill and Cowen, 2015), and enhancing selectivity (Zimmermann et al., 2007; Lehár et al., 2009a; Lehár et al., 2009b). In addition, drug combinations can promote effectivity of repositioning (Sun et al., 2016).

The use of repositioned drugs (approved by the FDA), with well-established data on bioavailability, safety, etc., allows accelerating drug development, significantly increasing the percentage of success, but reducing their costs (Zheng et al., 2018). Such innovations can be of great value in the therapy of neglected diseases, highly prevalent in South America, caused by parasitic protozoa (Müller and Hemphill, 2016), including CD (Palos et al., 2017).

The repositioning of a low-cost drug such as Disulfiram (DSF, Antabuse®) can be considered a “salvation” for global health care (Cvek, 2012). DSF, a drug used for the therapy of alcoholism, is
widely used and well tolerated in humans (Jørgensen et al., 2011; Sinclair et al., 2016) and is even considered less toxic than aspirin (Gessner and Gessner, 1992) and trials employing 200-250 mg/d daily or 800 mg/twice a week are regularly performed, with no reports of adverse effects (Sinclair et al., 2016). The DSF first derivative sodium diethyldithiocarbamate (DETC), also known as imuthiol, has been successfully used as an immunostimulant in HIV patients, reducing opportunistic infections (Hersh et al., 1991). DSF is used for different purposes (e.g. Kona et al., 2011), such as cancer therapy (Cvek, 2012; Meraz-Torres et al., 2020; Kannappan et al., 2021; Lu et al., 2021; Lu et al., 2022) and chemoprevention (Askgaard et al., 2014; Yang et al., 2015; Harrington et al., 2020). The DSF and/or DETC combination can enhance antitumoral activities of drugs such as cisplatin (O’Brien et al., 2012; Nechushtan et al., 2015), but diminish adverse reactions (Wysor et al., 1982; Elliott et al., 1983; Bodenner et al., 1986; Roemeling et al., 1986). In addition, DSF can overcome resistance, via different mechanisms (Schmidtova et al., 2019; Yang et al., 2019). The data presented here indicate that the BZ-DSF combination may comprise a promising alternative for CD therapy.

**Materials and methods**

**Drugs**

BZ (Nortec Química, Rio de Janeiro, Brazil) and DSF (Corden Pharma Bergamo S.p.A) were provided by Farmanguinhos (Fiocruz, Rio de Janeiro) and DETC was purchased from Sigma-Aldrich. Drugs were dissolved in dimethyl sulfoxide (DMSO) and stored at -20°C until use.

**Parasites and mammalian cells**

*T. cruzi* Y and the Colombiana strains epimastigote forms were maintained in LIT (Liver Infusion Trypticase) medium, supplemented with 10% fetal bovine serum (FBS), 100 µg/mL penicillin, and streptomycin at 25°C (dos Anjos et al., 2016). Cultures were harvested at the exponential growth phase. Then 5x10^5 parasites were incubated in the presence of the isolated compounds. Trypomastigote forms were obtained by cardiac puncture, at the peak of parasitemia of infected Swiss Webster mice (Sueth-Santiago et al., 2016) and maintained through coculture with epithelial cells, VERO, previously in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% FBS, at 37°C, 5% CO₂, as well as the amastigote form obtained after 8 days of cell infection (Monteiro et al., 2001). Axenic amastigotes were obtained from cell cultures of trypomastigotes in BHT medium incubated at 28°C, being collected after three passages of 56-64 h, in an initial concentration between 5x10^6 cells/mL (Engel et al., 1987). Macrophages from BALB/c mice were collected by peritoneal lavage in Hank’s balanced solution, seeded in 24-well plates or bottles (Falcon, New Jersey, USA), and kept at 37°C in atmosphere of 5% CO₂ in DMEM medium supplemented with 10% FBS.

**Parasite-host interaction**

Assays were performed using a parasite:cell ratio of 10:1, and infection quantification was performed by direct counting cultured cells Giemsa (Laborklin) -stained coverslips under light microscopy, approximately 1000 cells per coverslip. Association indices (AI) were obtained by multiplying the percentage of infected macrophages by the average number of parasites per host cell, as previously described (Martiny et al., 1996).

**In vitro evaluation of trypanocidal activity and cytotoxicity**

*T. cruzi* epimastigotes (10^7 cells/mL) incubated with DETC and BZ, to determine IC₅₀ values each drug, at 24 h at 28°C, determined by the Alamar Blue assay at 570 nm and 600 nm. For the combinations, both for trypanocidal activity and for the selectivity index (10^7 Swiss Webster mouse peritoneal macrophages/mL), six fixed doses were prepared based on the IC₅₀ value of the isolated drugs, in the proportions 5:0, 4:1, 3:2, 2:3, 1:4 and 0:5 (Fivelman et al., 2004). Concentration-response curves were plotted and the IC₅₀ and CC₅₀ values of the compounds (inhibition and cytotoxicity, respectively), alone or in combination, were calculated using GraphPad Prism, 7.

**ROS detection**

ROS were detected using the H₂-DCFDA probe using a confocal microscope Fluoview 1000, Olympus.

**Lipid peroxidation**

Lipid peroxidation was determined by the production of thiobarbituric acid (TBA) reactive substances (TBARS), by parasites incubated or not in the presence of the compounds for 24 h. Subsequently, the cells were centrifuged three times in phosphate-buffered saline (PBS). After washing, the parasites were resuspended in 200 µL PBS and 200 µL TBA at a final concentration of 1%. After homogenization, the material was incubated at 99°C for a period of 3 h and measured in a spectrophotometer at 532 nm (Menezes et al., 2006).
Thiol group measurements

The determination of the concentration of low molecular weight thiols was carried out using 5,5′-dithiobis (2-nitrobenzoic acid) (DTNB) and methanol assay after protein removal with 10% trichloro acetic acid. Subsequently, the supernatant was read in a spectrophotometer at 412 nm (Hitachi U-1100), as previously described (Sedlak and Lindsay, 1968).

Dosage of superoxide dismutase

Parasite samples untreated and treated with DETC alone and in combination with BZ, for 1 and 24 hours, were evaluated using a colorimetric method for superoxide dismutase (SOD) measurement (Sigma-Aldrich Kit-WST- SOD Assay), which is based on the generation of the radial superoxide from the xanthine-xanthine oxidase (XOD) system, where the superoxide reacts with the sample and converts the tetrazolium salt to formazan. After reactions, the measurements spectrophotometrically performed in a VersaMax at 440 nm (Moukdar et al., 2009).

Electron microscopy

Parasites were washed with PBS and fixed in Karnovsky for 24 h, at 4°C. Then, samples were post-fixed in 1% osmium tetroxide, 5 mM calcium chloride, and 0.8% potassium ferricyanide in 0.1M sodium cacodylate buffer, protected from light for 40 min at room temperature. For scanning, electron microscopy (SEM) samples were dehydrated in ethanol series, critical point-dried, mounted on stubs, gold-metalized, and observed in a JEOL 5310 scanning electron microscope. For transmission, electron microscopy (TEM) samples were dehydrated in acetone and embedded in Polybed epoxy resin (Polysciences, Inc). After 72 h at 60°C, the samples were sectioned on an ultramicrotome (Reichert, Leica), using a diamond knife (Diatome, Hatfield, PA), and the sections were collected on 300 mesh copper grids and counterstained with 3% lead citrate and 5% uranyl acetate in water. Samples were observed in a transmission electron microscope Zeiss EM 109 at 80kV, as previously described (Vannier-Santos and Lins, 2001).

In vivo infection

Swiss Webster mice were infected with Y or Colombian strain, intraperitoneally (i.p.), with 10⁴ bloodstream trypomastigotes. The infected animals were divided into the following groups (15 animals per group): positive control (BZ); negative control (PBS + 1% Kolliphor); DETC + BZ combination; DSF + BZ. The therapy was initiated 5 days from the beginning of the parasitemia and carried out for 30/60 days, administered through the intragastric route (Salomão et al., 2010). Parasitemia was verified by direct microscopic, slide analysis of parasites in 5 µL of blood, and mortality rates were checked daily/weekly up to 30 days post-treatment.

Systemic toxicity

Thirty days after the end of the treatment, uninfected mice blood was collected through the brachial plexus and stored at -80°C for biochemical analysis of the enzymes: urea, for renal monitoring, total creatine kinase (CK), for evaluation of cardiac or skeletal musculature lesions, alanine aminotransferase (ALT) and aspartate aminotransferase (AST), assessment of liver damage, all being determined in whole blood by the Reletron® reactive test strip system (Roche Diagnostics, F Hoffmann-La Roche Ltd, Basel, Switzerland) using reflectance photometry (Salomão et al., 2010).

Histopathology

Tissue samples were fixed in formaldehyde solution pH 7.2, embedded in paraffin, and 5 µm-thick sections were stained with hematoxylin and eosin (H&E) and picrosirius red to stain collagen fibers (Andrade et al., 1994).

Statistical analysis

The data obtained are representative of at least three independent experiments carried out in triplicate. Statistically significant differences were analyzed using the ANOVA test and Tukey or Dunn post-tests with p < 0.05, using GraphPad Prism, 7.

Results

DETC inhibited dose-dependently the axenic proliferation of epimastigote forms (Figure 1). The IC₅₀ value obtained was 1.48 µM. The BZ IC₅₀ observed was 2.28 µM (Table 1). The selectivity indexes revealed that the combination selectivity was increased over an order of magnitude (about 13-fold), as compared to the drug of choice, BZ. Based on the IC₅₀ values obtained DETC and BZ were combined at different proportions. Isobolograms were plotted to analyze the possible synergism between BZ and DETC on the trypanocidal activity. There was synergistic activity, particularly at 3:2 and 2:3 concentration ratios (Figure 2). Afterward, we observed that 5 µM of either BZ or DETC significantly inhibited parasite growth, whereas the combination of 2.5 µM of each compound was even more effective (Figure 3). In order to approach the DETC effects upon general parasite structure, we employed scanning
electron microscopy. DETC-treated epimastigotes were often bizarrely shaped, eventually presenting surface discontinuities and reduced cell body volume (Figure 4). We used transmission electron microscopy to determine the DTEC effects on epimastigote subcellular architecture. DETC-treated parasites displayed remarkably enlarged endoplasmic reticulum (ER) cisternae as well as reduced mitochondrial electron density (Figure 5). Morphometric analysis indicated the ER lumen was enhanced over 1000-fold (not shown). Some parasites displayed disorganized kinetoplast DNA and loss of cell ultrastructural compartmentation.

In order to approach reactive oxygen species (ROS) production in DETC-treated parasites, we used fluorescent probes. Incubation with DETC remarkably enhanced H$_2$DCFDA staining under fluorescence microscopy (Figure 6) and labeling was found in sub-cellular compartments, rather than whole cell. To evaluate the oxidative stress consequence, we measured lipoperoxidation using the TBARS assay (Figure 7). We observed that both BZ and DETC had little effect ($p > 0.05$) on lipid peroxidation, but it was significantly ($p < 0.05$) increased by their combination. Since sulfhydryl groups are largely involved in the redox regulation in trypanosomatid parasites, we measured thiol expression using the colorimetric Ellman’s reaction. DETC diminished thiol expression in the parasite (Figure 8). The biochemical colorimetric approach indicates that DETC produce a dose-dependent effect and that the
isolated compounds reduced SH levels ($p < 0.05$), but the combination was more effective ($p < 0.01$). As DETC is well-known for its SOD inhibiting capacity, we measured SOD activity in vitro and in vivo, in murine infection, before and after DETC treatment (Table 2). Interestingly, the combination was more inhibitory, and the effects in vitro were more pronounced.

As the Y strain is sensitive to BZ, we decided to test the DETC susceptibility of axenic amastigotes of both Y and Colombiana strains. Although the Colombiana strain, naturally resistant to BZ, was less sensitive to DETC at 0.8-3 µM ($p < 0.05$), the effects were highly significant ($p < 0.01$) at 5 µM. Both strains showed significantly decreased parasite survival in a dose-dependent manner (Figure 9).

In order to test the effects of the combination in intracellular parasites, we infected murine macrophages with blood trypomastigotes in the presence or in the absence of DETC (Figure 10). We noticed that 10 µM DETC remarkably reduced the monolayer parasite load, and a DETC-BZ combination at 5 µM concentration was equally or even more effective.

---

**TABLE 1** Trypanocidal activity, cytotoxicity, and selectivity indexes of the DETC + BZ combination after 24 h of treatment.

| Combination ratio (DETC : BZ) | Cytotoxicity (peritoneal cells) | Trypanosoma cruzi (Y) epimastigotes | Selectivity indexes |
|------------------------------|---------------------------------|-------------------------------------|---------------------|
|                              | $CC_{50}$ (µM)                  | $IC_{50}$ (µM)                      |                     |
| 5:0                          | 2.09                            | 1.48                                | 1.41                |
| 4:1                          | 20.06                           | 0.67                                | 29.94               |
| 3:2                          | 147.00                          | 1.48                                | 99.32               |
| 2:3                          | 0.58                            | 0.30                                | 1.93                |
| 1:4                          | 1.03                            | 1.68                                | 0.61                |
| 0.5                          | 17.54                           | 2.28                                | 7.69                |

The $CC_{50}$ and $IC_{50}$ values of the combination were calculated from the cytotoxicity and inhibition assay, respectively, using Alamar Blue.
To approach the activity of the combination *in vivo*, we tested the murine infection for 30-60 days. The parasitemia of animals infected with both Y and Colombiana strains was reduced by the BZ-DSF combination (Figure 11) as compared to BZ low concentrations (20/50 mg/kg). The cumulative survival of the animals treated with the 10 mg/kg/day (each) DETC-BZ combination was increased by circa 6-fold (*p* < 0.01) as compared to BZ alone (Figure 12). We used histopathology to evaluate the murine infection. Contrary to animals treated with low BZ concentration (10 mg/kg/d) the ones incubated with the combination (10 mg/kg/d BZ + 10 mg/kg/d DETC) showed no amastigote nests in myocardium (Figure 13). The Sirius red staining was employed to assess tissue fibrosis. Animals treated with the combination displayed less, and focal fibrosis, whereas mice treated with BZ alone showed intense fibrosis staining. To evaluate the systemic toxicity of the treatments we measured the plasma levels of ALT, AST, CK, and urea. Measurements demonstrated (Figure 14) that the combination at 10 mg/kg/day (each) was not as toxic than the isolated drugs at 20 mg/kg/day.

**Discussion**

CD remains a major public health problem, as most of the infected people and domestic animals such as dogs, important reservoir hosts (Enriquez et al., 2014; Castillo-Neyra et al., 2015), are not treated or diagnosed (Dias et al., 2016). Since both drugs employed in CD chemotherapy are remarkably toxic (Castro and Diaz de Toranzo, 1988; Castro et al., 2006), therapy is frequently associated with severe adverse reactions, often causing treatment suspension (Levi et al., 1996; Olivera et al., 2017; Guggenbühl Noller et al., 2020; Pérez-Molina et al., 2021). Development of new safe and low-cost therapeutic alternatives is urgently required. Drug repositioning and combinations
comprise valuable tools for overcoming CD monotherapy limitations (e.g., Aguilera et al., 2019).

Both DETC and DSF express antiparasitic activities upon *T. cruzi* (Lane et al., 1996; de Freitas Oliveira et al., 2021; de Freitas Oliveira et al., 2022) and *Leishmania* (Khouri et al., 2010; Celes et al., 2016; Mazur et al., 2019). In macrophage cultures, DETC caused destruction of intracellular amastigotes with little effect on macrophage spreading pattern. Similarly, in the murine infection, the combination reduced parasitemia and significantly (*p* < 0.001) enhanced animal survival by circa 6-fold. Synergistic combinations can enhance selectivity (Zimmermann et al., 2007; Léhar et al., 2009a; Léhar et al., 2009b). In fact, the BZ + DETC combination was synergistic *in vitro* and *in vivo* and produced over 10-fold selectivity index increase. Such synergistic activities may be caused by the prooxidant effects of BZ (Pedrosa et al., 2001; Rigalli et al., 2016), associated with the antagonism of antioxidant defenses of DSF and that can allow dosing reduction (Bustamante et al., 2014), presumably leading to decreased adverse reactions. Besides, DSF and DETC were shown to reduce adverse reactions of other drugs (*vide supra*). Here we observed that reduced combined drug concentrations did not impair effectivity. Therefore, such combinations may lead to the development of safe and effective medications.

Since one of the major problems in CD therapy is the prompt rise of resistance, we tested the combination in axenic amastigotes as well as in infected macrophages, not only of the Y strain but also of the Colombiana one, highly drug-resistant (Andrade et al., 1985). Interestingly, both strains were sensitive to the thiocarbamates at low µM range. Drug combinations were employed for overcoming drug resistance rising but were not effective in leishmaniasis (García-Hernández et al., 2012) or malaria (Wongsrichanalai et al., 2002) and drug combinations were not effective upon drug-resistant *T. cruzi* (Bustamante et al., 2014).

CD treatment is confronted with growing frequencies of refractory cases. Over 60% of *T. cruzi* strains isolated in Colombia display some degree of BZ resistance (Mejía-Jaramillo et al., 2012) and strains isolated in the Brazilian Amazon show natural resistance to this drug (Teston et al., 2013). The rise of readily acquired (Neal and van Bueren, 1988; Mejia et al., 2012) or natural resistance (Zingales, 2018) significantly limit the therapeutic success of CD. Thus, a major relevance of the DSF + BZ stems from the potential revert drug resistance phenotypes, by inhibiting both activity (Loo et al., 2004; Sauna et al., 2004) and expression (Loo and Clarke, 2000) of p-glycoproteins, which are involved in *T. cruzi* drug resistance (Campos et al., 2013).
FIGURE 6
Detection of cellular reactive oxygen species (ROS) in T. cruzi epimastigote forms (Y strain) using the H₂DCFDA probe accessed by fluorescence microscopy (B, D). (A, B) - Control and (C, D) - 10µM DETC-treated. (A, C) - phase contrast images. Note intense and compartmented staining in DETC-treated parasites. Magnification - 400X.

FIGURE 7
Measurement of lipid peroxidation in T. cruzi epimastigote forms (Y strain) by determination of thiobarbituric acid reactive substances (TBARS). Parasite cells treated with 10 µM DETC and 10 µM BZ combination for 24 h presented a significantly (*p < 0.05, ANOVA and Dunn’s post-test) increased lipoperoxidation. Bars represent mean ± SD (n = 4).
Besides ABC cassette pumps (Zingales et al., 2015), natural resistance may rely on aldo-keto reductase and alcohol dehydrogenase (González et al., 2017). In this regard, it is important to notice that DSF inhibits alcohol dehydrogenase activity (Carper et al., 1987) and decreases the expression of aldo-keto reductase accessed by proteomic analysis (Yoshino et al., 2020). In addition, glutathione (GSH) forms conjugates with different drugs that are extruded by ABC transporters (Jedlitschky et al., 1994; Loe et al., 1998), so GSH and trypanothione (TSH) are implicated in detoxication of both NFX and BZ (Repetto et al., 1996). DSF can act as a glutathionylation agent (Hirschenson and Mailloux, 2021). Similarly, DETC derivatives form conjugates with GSH via carbamoylation (Ningaraj et al., 1998) and this reaction inhibits glutathione reductase (Miller and Blakely, 1992).

T. cruzi ABC proteins externalize thiol-drug conjugates (da Costa et al., 2018) and inhibition of GSH and so TSH synthesis by buthionine sulfoximine (Maya et al., 2004; Fauández et al., 2005; Vázquez et al., 2017) augments the effectivity of trypanocidal agents BZ and nifurtimox (Fauández et al., 2005; Fauández et al., 2008). Interestingly, DSF/DETC can diminish reduced GSH levels (Strömme, 1963; Ohno et al., 1990; Nagendra et al., 1994; Mittal et al., 2014) and GSH/TSH depletion can trigger T. cruzi programmed cell death (Piacenza et al., 2007). Here we observed reduced low mol. wt. thiol levels in DETC-treated

Table 2 Evaluation of T. cruzi superoxide dismutase (SOD) activity in presence of DETC in vitro and DSF in vivo isolated and combined to BZ.

| Assay                  | SOD activity (U/mL) |
|------------------------|---------------------|
|                        | Untreated (1% kolliphor) | BZ (100 µM) | DETC (100 µM) | BZ + DETC (50:50 µM) |
| In vitro1 1h           | 2.975               | 2.821       | 3.056         | 2.103**               |
| In vitro1 24h          | 0.896               | 0.705       | 0.773*        | 0.734*                |
| Un-treated (1% kolliphor) | 0.059               | 0.059       | 0.058         | 0.063                 |
| BZ (50 mg/kg)          | 0.058               | 0.058       | 0.063         | 0.052                 |
| DSF (100 mg/kg)        |                    |             |              |                      |
| BZ + DSF (50:50 mg/kg) |                    |             |              |                      |
| BZ + DSF (50:100 mg/kg)|                    |             |              |                      |

1T. cruzi epimastigote forms (Y strain), treated or not with DETC isolated or in combination with BZ, spectrophotometrically measured.

2SOD activity of trypomastigote (Y strain)-infected mice treated for 3 consecutive days. * p < 0.05 and ** p < 0.01 ANOVA and Dunn’s post-test (n = 3).

Besides ABC cassette pumps (Zingales et al., 2015), natural resistance may rely on aldo-keto reductase and alcohol dehydrogenase (González et al., 2017). In this regard, it is important to notice that DSF inhibits alcohol dehydrogenase activity (Carper et al., 1987) and decreases the expression of aldo-keto reductase accessed by proteomic analysis (Yoshino et al., 2020). In addition, glutathione (GSH) forms conjugates with different drugs that are extruded by ABC transporters (Jedlitschky et al., 1994; Loe et al., 1998), so GSH and trypanothione (TSH) are implicated in detoxication of both NFX and BZ (Repetto et al., 1996). DSF can act as a glutathionylation agent (Hirschenson and Mailloux, 2021). Similarly, DETC derivatives form conjugates with GSH via carbamoylation (Ningaraj et al., 1998) and this reaction inhibits glutathione reductase (Miller and Blakely, 1992). T. cruzi ABC proteins externalize thiol-drug conjugates (da Costa et al., 2018) and inhibition of GSH and so TSH synthesis by buthionine sulfoximine (Maya et al., 2004; Fauández et al., 2005; Vázquez et al., 2017) augments the effectivity of trypanocidal agents BZ and nifurtimox (Fauández et al., 2005; Fauández et al., 2008). Interestingly, DSF/DETC can diminish reduced GSH levels (Strömme, 1963; Ohno et al., 1990; Nagendra et al., 1994; Mittal et al., 2014) and GSH/TSH depletion can trigger T. cruzi programmed cell death (Piacenza et al., 2007). Here we observed reduced low mol. wt. thiol levels in DETC-treated
Effect of DETC alone or combined with BZ on the T. cruzi-macrophage interaction. BALB/c mice peritoneal macrophages were infected with Colombiana strain bloodstream trypomastigote forms 1:10 phagocyte/parasite ratio. Control cultures (A) showing several parasitized macrophages as well as larger number of intracellular forms per phagocyte (arrowheads) than cells treated with the combination 5 µM DETC + 5 µM BZ (B). Magnification 200X. The association index in cultures treated with 10 µM BZ or the 5 µM DETC + 5 µM BZ combination after 24 hours of incubation (C) was significantly (***p < 0.001, ANOVA and Dunn’s post-test) reduced. A slightly greater inhibition was observed in cultures incubated with the combination, despite the reduced concentrations. Bars represent mean ± SD.

Parasitemia of Swiss Webster mice infected with T. cruzi blood trypomastigotes, Y strain (A, B) and Colombiana (C). The animals were infected with 10⁵ blood trypomastigotes/mL, strain Y, treated for 60 days with vehicle; low doses of BZ (20 mg/kg); DETC (20 mg/kg) or a combination of BZ + DETC (20:20 mg/kg), orally. *p < 0.05 and **p < 0.01 ANOVA test and Dunn’s post-test (A). Parasites treated with vehicle; BZ (50 mg/kg); DSF (50 mg/kg); combination of BZ + DSF (50:50 mg/kg); and BZ + DSF (50:100 mg/kg), administered for 10 consecutive days (B, C, p > 0.05). Insert shows data in a different scale. The parasites were counted daily (A) or weekly (B, C) on Neubauer chambers and the graphs were plotted in GraphPad Prism, 7.

Monitoring the cumulative survival of mice infected intraperitoneally with 10⁵ T. cruzi blood trypomastigote/mL (Y strain) of and treated with 10 mg/kg/day of DETC and BZ alone or in combination, p.o. daily for 60 consecutive days. Note that animals treated with the combination had a survival rate of 60%, whereas the group treated with BZ was 10% and the control group died on the 14th day. ***p < 0.001 ANOVA and Tukey post-test.
FIGURE 13
Histopathological analysis (H&E) of murine myocardium T. cruzi (Y strain)-infected mice, treated for 60 consecutive days, p.o. with vehicle (A); 10 mg/kg/d BZ-treated and (B) treated with the of 10 mg/kg/d DETC combined to 10 mg/kg/d BZ (C). Amastigote nests were observed in A and B (arrowheads). Skeletal muscle of mice infected with Colombiana strain, for 100 d and treated for 30 consecutive days orally with 20 mg/kg/d BZ (D), 20 mg/kg/d DSF (E) or combination of 10 mg/kg/d each (F). Picro Sirus red staining was employed to demonstrate fibrosis. The combination using lowered concentrations was associated with reduced fibrosis (F). Magnification: 200X.

FIGURE 14
Systemic toxicity of mice treated with DSF and BZ, alone and in combination, by determining blood levels of creatine kinase (A), urea (B), alanine aminotransferase (C) and aspartate aminotransferase (D); after 20 mg/kg BZ or DSF and the 10 mg/kg/d BZ + 10 mg/kg/d DSF. Contrary to isolated drugs, the combination, employing lowered dosages, did not increase plasma levels.
T. cruzi, by colorimetric and cytometric approaches, presumably by the formation of DS/DETC thiol-mediated conjugates with GSH (Jin et al., 1994). Similarly DSF reducing GSH levels, potentiate antiparasitic activity in malaria experimental models (De Jongh, 1953a; De Jongh, 1953b; Deharo et al., 2003). Therefore, the use DSF may overcome T. cruzi drug-resistance via different mechanisms.

The ultrastructural analysis performed here revealed surface membrane discontinuities, which may be explained by lipid peroxidation, corroborated by TBA determination, and the cell surface damage may lead to loss of cytoplasmic content culminating in necrosis and cell collapse observed by SEM. The analysis by TEM revealed remarkable damage on parasite ER and mitochondria, redox-active organelles. Oxidative stress induces ER stress (Liu et al., 2019; Esmaeili et al., 2022) and DSF triggers ROS-dependent ER stress (Shah O’Brien et al., 2019). The ER stress is related to the mitochondrial one (Wang et al., 2016; Kim et al., 2022; Yuan et al., 2022) and the latter can be promoted by the DETC-mediated SOD inhibition as well as by the reductions in GSH levels.

DSF causes ER stress associated with ROS production (Shah O’Brien et al., 2019). ER stress may cause the organelle cisternae dilation (Montalbano et al., 2013), which are not as conspicuous as the remarkable enlargement observed in T. cruzi here, i.e., up to over 1000-fold, revealed by ultrastructural morphometry (not shown) and much higher than observed on mammalian cells. Such difference may be explained at least in part by a selective mechanism of action. It is noteworthy that ER stress was shown to be implicated in the CD cardiomyopathy in a murine model (Ayyappan et al., 2019). DETC can enhance ER stress in a kidney model (Kang et al., 2020), whereas its derivative DETC-MeSO (S-methyl-N, N-diethylthiocarbamate sulfoxide) can decrease ER stress markers in a stroke rat model (Mohammad-Gharibani et al., 2014).

The ubiquitin system comprises therapy target in diverse disorders (Wertz and Wang, 2019), and proteasome can be exploited as chemotherapy target for parasitic protozoa (Cromm and Crews, 2017; Xie et al., 2019). Parasite COP9 signalosomes comprise potential targets for chemotherapy (Ghosh et al., 2020). Interestingly DSF inhibits the ubiquitin-proteasome system (Czek and Dvorak, 2008; Kona et al., 2011). The ER stress-associated cisternae dilation can be detected by EM (Riggs et al., 2005; Akizumama et al., 2009), so we employed the ultrastructural approach to help elucidating antiparasitic agents’ mechanisms of action (Vannier-Santos and De Castro, 2009). The inhibition of proteasome function causes the accumulation of precursor proteins within ER cisternae (Hoefer and Groettrup, 2021) and accumulation of misfolded proteins may cause ER dilation (Sun et al., 2014) and trigger oxidation-reduction futile cycles producing H$_2$O$_2$ and depleting reduced GSH pools in the ER (Malhotra et al., 2008).

The T. cruzi intracellular Ca$^{2+}$ homeostasis is an important therapeutic target (Benaim et al., 2020) and calcium can be transferred from the ER to mitochondria during stress via mitochondria associated membranes (MAM), also termed ER–mitochondria encounter structure (ERMES), and the Ca$^{2+}$ overload may be implicated in mitochondrial damage (Mohsin et al., 2020). We have previously described the ER-mitochondria connection in Leishmania braziliensis treated with histone deacetylase (HDAC) inhibitors, including the nuclear envelope in the trypanosomatid parasite (Angelo de Souza et al., 2020). HDAC inhibitors cause ER stress (Chen et al., 2017) and lead to the formation of mitochondria-ER tight binding, associated with ER cisternae enlargement, but it was much less pronounced than reported here. A similar mitochondria-ER association was detected here (Figure 5E), but since both compartments were remarkably enlarged, an eventual connection interpretation could be misleading.

Like the ER alterations, the DETC mitochondrial effects observed on the parasite cells were not detected on the mammalian cells, as previously reported in Leishmania-infected macrophage (Khouri et al., 2010). Remarkably enlarged mitochondria with washed out matrix were previously observed in both T. cruzi (Menezes et al., 2006) and Leishmania amazonensis (Vannier-Santos et al., 2008) exposed to 1,4-diamino-2-butane a biocide that impairs the T. cruzi redox homeostasis (Soares et al., 2012) and induces lipoperoxidation (Menezes et al., 2006; Vannier-Santos et al., 2008). This putrescine analogue can inhibit polyamine transport and biosynthesis, affecting numerous parasite cell functions (Vannier-Santos and Suarez-Fontes, 2017), therefore involving different pharmaceutical targets (Roberts and Ullman, 2017). Polyamines play a pivotal role in trypanosomatid parasites, including the antioxidant protection from lipid peroxidation (Hernández et al., 2006). Also, this polycation metabolism is important for the antioxidant role of the spermidine-GSH adduct Trypanothione (N1, N8-Bis(glutathionyl)spermidine, TSH). TSH metabolism and SOD are drug targets for T. cruzi infection (Beltran-Hortalano et al., 2017; Píñeyro et al., 2021). Both NFX and BZ interfere with TSH metabolism (Maya et al., 1997; Maya et al., 2007), and TSH confers T. cruzi resistance to BZ and NFX (Maya et al., 2004; Fautè et al., 2005; Mesias et al., 2019). TSH and tryparedoxin take part in BZ-resistance (González-Chávez et al., 2019) and the enzyme comprises a drug target (González-Chávez et al., 2015).

The fluorescent probe H$_2$DCFDA labeling indicates the ROS production and the oxidative stress triggering may be due both to SOD inhibition by DETC (Heikkila et al., 1976; Heikkila et al., 1978) as well as to lowering reduced glutathione levels (vide supra). The DSF-mediated glutathionylation enhances the O$_2$. and H$_2$O$_2$ production in mitochondria (Hirschenson and Malilou, 2021) and SOD inhibition was previously shown to reduce T. cruzi parasitemia in murine infection (Olmo et al., 2015). The SOD inhibition observed here was significant on the parasite in vitro, but not in vivo, again possibly indicating a selective mechanism. Interestingly, the T. brucei SOD gene sodb1
deletion increases sensitivity to NFX and BZ (Prathalingham et al., 2007) and SOD inhibition enhances NFX antitumoral activity (Koto et al., 2011). In this regard, the DSF and DETC strongly inhibit T. cruzi SOD (Giulivi et al., 1988), and is trypanocidal (de Freitas Oliveira et al., 2021), also exerting leishmanicidal effects (Khouri et al., 2010). Interestingly, the T. cruzi Fe-SOD is found within parasite mitochondria, preventing programmed cell death (Piacenza et al., 2007). The immunofluorescence labeling of TcSOD in the parasite kinetoplast is relevant since it can preclude DNA fragmentation (Piacenza et al., 2007). In the TEM images shown here, we observed DETC-treated parasites with kDNA disorganization as well as mitochondrial damage. In this regard, arginase inhibition, causing redox imbalance, lead to kDNA disorganization in Leishmania (Cruz et al., 2013). SOD downmodulation may pose a dual advantage in CD therapy, since the enzymes are involved in intracellular survival, as scavenge mechanism from macrophage production of superoxide (Martinez et al., 2019), but also drug resistance (Nogueira et al., 2006; Campos et al., 2014; Campos et al., 2017). In this regard, the Sirtuin 7TcSir2p3 induces the overexpressing TcFeSOD-A activities increasing T. cruzi resistance to BZ and NFX (dos Santos Moura et al., 2021).

Thiocarbamates chelate copper and trigger its accumulation and lipid peroxidation (Tonkin et al., 2004; Valentine et al., 2009; Viquez et al., 2009). Besides, copper-containing nanoparticles trigger oxidative stress and ER stress (Liu et al., 2021). Copper chelated by DSF induces cancer cells apoptosis in a ROS and mitochondria-dependent manner (Ren et al., 2021).

Ferroptosis is a progranulated cell death mechanism (Stockwell et al., 2017) characterized by mitochondria with enhanced matrix electron density and swollen cristae (Dixon et al., 2012). Such alterations were observed by TEM here, so this mechanism may be triggered by DSF. It should be kept in mind that different cell death mechanisms such as necrosis, apoptosis, and autophagy may be triggered simultaneously (dos Anjos et al., 2016). Interestingly, in a murine model of sepsis, the induction of pyroptosis and ferroptosis is associated with downregulation of the mitochondrial aldehyde dehydrogenase (Gao et al., 2022) and since DSF and DETC inhibit this enzyme (Detrich and Erwin, 1971) may also trigger ferroptosis on parasite cells.

Inhibition of cysteine uptake, employed in GSH (Badgley et al., 2020) synthesis, transport causes ER stress associated with ferroptosis in cancer cells (Dixon et al., 2014) and trypanoloxurpoxidase-deficient Trypanosoma brucei parasites undergo ferroptosis (Bogacz and Krauth-Siegel, 2018). Mitochondria are involved in cysteine-deprivation leading to ferroptosis (Gao et al., 2019).

The drug combination using DSF offers important advantages, which may be both economical (Cvek, 2012; Soave et al., 2016) and pharmacological, since this compound protects normal cells (Jia and Huang, 2021), can diminish the toxicity of different drugs such as cis-diaminedichloroplatinum (Wyssor et al., 1982), including myocardial protection (Sonawane et al., 2018) and circa 30% of the CD patients develop heart disease, characterized by arrhythmias among other cardiac manifestations (Saraiva et al., 2021). It is worth mentioning that DSF can suppress cardiac arrhythmogenesis (Sander et al., 2021). Nevertheless, DETC and DSF were reported to cause neuropathies (Worner, 1982; Frisoni and Di Monda, 1989). In addition, BZ and NFX may cause neuropsychiatric reactions (Jackson et al., 2020). In this regard, it is noteworthy that DSF and its derivatives were also reported to act as neuroprotective agents (Zhao et al., 2000; Ningaraj et al., 2001; Libeu et al., 2012; Mohammad-Gharibani et al., 2014; Prentice et al., 2015). The eventual neurotoxic activity may be due at least in part to high dosages used in the past (Gessner and Gessner, 1992) and oxidative stress produced by copper accumulation leading to lipid peroxidation (Tonkin et al., 2004), although DSF may exert antioxidant effects (Kyle et al., 1989). This property is relevant since both BZ (Pedrosa et al., 2001; Rigalli et al., 2016) and CD (de Oliveira et al., 2007; Gupta et al., 2009) are associated with oxidative stress.

Histopathological samples revealed no amastigote nests detected in tissues of animals treated with low doses of the DSF-BZ combination, which showed mild inflammatory infiltrates and did not display significant fibrosis as assessed a by the picrosirius red staining. CD is an inflammatory infection (Talvani and Teixeira, 2011) associated with fibrosis and pyroptosis (Cerbàn et al., 2020). The T. cruzi infection leads to ROS formation in the mitochondria, triggering PARP-1 and NF-kappaB activation, culminating in the production of pro-inflammatory cytokines such as IL-12 and IFN-g (Ba et al., 2010), involved in cardiomyopathy pathophysiology (Cunha-Neto et al., 1998). In this regard, DSF is anti-inflammatory (Kanai et al., 2011), of potential use for inflammatory disorders (Guo et al., 2022), inhibiting oxidative stress and inflammassome activation, preventing cardiac damage (Wei et al., 2022), suppressing fibrosis (Zhang et al., 2021) and pyroptosis (Hu et al., 2020; Li et al., 2022; Zhou et al., 2022). The immune response to T. cruzi infection associated with myocardial fibrosis involves TGF-β (Chaves et al., 2019), and this cytokine comprises a therapeutic target in the CD cardiac damage (Waghabi et al., 2022). In this regard, DSF can inhibit TGF-β receptor signal transduction (Jiang et al., 2021).

Systemic toxicity assays based on the measurement of plasmatic CK, AST, ALT, and urea indicate decreased or insignificant toxicity. DSF was shown to reduce toxicity of several drugs such as cis-diaminedichloroplatinum, a property termed “disulfiram rescue” for saving the treated organism (Wyssor et al., 1982; Roenelning et al., 1986). DETC is also considered a rescue agent (Gandara et al., 1990).

Because of promising in vitro and in vivo results, we are starting a clinical trial with the DSF-BZ combination (Saraiva et al., 2021), comprising a bona fide translational approach.
Taken together, the present data and the cytoprotective capacity of DSF/DETC as well as the resistance reversion potential, such a combination may be safe and effective, even in refractory CD cases.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The animal study was reviewed and approved by Comissão de Ética no Uso de Animais do Instituto Oswaldo Cruz/Fiocruz lic. no. L012/2020.

Author contributions

JA-S, DM, JF, MA, and DV-d-S: experiment execution; RS, AV, SP, AS-F: Data interpretation, discussion and translational research planning; SA, Histopathological analysis; MV-S: Project conception, study planning, funding obtaining, student supervision, microscopy interpretation; discussion. All authors contributed to the article and approved the submitted version.

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), grant number 314717/2020 and Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ) grant number 206475/2021, 259286/2021, provide most of the scholarships of the team as well as consumables used in the experiments. Oswaldo Cruz Institute (IOC)/Oswaldo Cruz Foundation (Fiocruz) provides the general infrastructure and supports the open access publication fees.

Acknowledgments

The authors acknowledge the valuable partnership of Farmanguinhos and INI/Fiocruz as well as the contributions FIOCRUZ technological platforms. To Dr. Marcus Fernandes Oliveira for valuable discussions and critical reading of the manuscript.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

Aguilera, E., Alvarez, G., Cerecetto, H., and González, M. (2019). Polyplopharmacology in the treatment of Chagas disease. Curr. Med. Chem. 26 (23), 4476–4489. doi: 10.2174/0929867325666180410101728

Akiyama, M., Hatanaka, M., Ōhta, Y., Ueda, K., Yanai, A., Uehara, Y., et al. (2009). Increased insulin demand promotes while pioglitazone prevents pancreatic β cell apoptosis in Wfs1 knockout mice. Diabetologia 52 (4), 653–663. doi: 10.1007/s00125-009-1270-6

Andrade, S. G., Kloertel, J. K., Borges, M. M., and Ferrans, V. J. (1994). Morphological aspects of the myocarditis and myositis in Calomys callosus experimentally infected with Trypanosoma cruzi: fibrogenesis and spontaneous regression of fibrosis. Mem. Inst. Oswaldo Cruz. 89 (3), 379–393. doi: 10.1590/S0074-02761994000300017

Andrade, S. G., Magalhães, J. B., and Pontes, A. L. (1985). Evaluation of chemotherapy with benzimidazole and nifurtimox in mice infected with Trypanosoma cruzi strains of different types. Bull. World Health Organ. 63 (4), 721–726.

Ángelo de Souza, L., Silva e Bastos, M., de Melo Aprigino, J., Souza Onofre, T., Apaza Calla, L. F., Hamburg, T., et al. (2020). Histone deacetylases inhibitors as new potential drugs against Leishmania braziliensis, the main causative agent of new world tegumentary leishmaniasis. Biochem. Pharmacol. 180, 114191. doi: 10.1016/j.bcp.2020.114191

Askgaard, G., Friis, S., Hallas, J., Thrygesen, L. C., and Pottgang, A. (2014). Use of dasilifiram and risk of cancer. Eur. J. Cancer Prev. 23 (3), 225–232. doi: 10.1097/CEJ.0b013e3283647466

Ayrapapp, J. P., Lizardo, K., Wang, S., Yurkow, E., and Nagajyothi, J. F. (2019). Inhibition of ER stress by 2-aminopurine treatment modulates cardiomyopathy in a murine chronic Chagas disease model. Biomol Ther. (Seoul). 27 (4), 386–394. doi: 10.4062/biomolther.2018.193

Badgley, M. A., Kremer, D. M., Maurer, H. C., DelGiorno, K. E., Lee, H. J., Purohit, V., et al. (2020). Cysteine depletion induces pancreatic tumor ferroptosis in mice. Science 368 (6486), 85–89. doi: 10.1126/science.aaw9872

Ba, X., Gupta, S., Davidson, M., and Garg, N. J. (2010). Trypanosoma cruzi induces the reactive oxygen species-PARP-1-RelA pathway for up-regulation of cytokine expression in cardiomyocytes. J. Biol. Chem. 285 (15), 11596–11606. doi: 10.1074/jbc.M109.076984

Beltran-Hortelano, I., Alcolea, V., Font, M., and Perez-Silanes, S. (2022). Examination of multiple Trypanosoma cruzi targets in a new drug Discov approach for Chagas disease. Bioorg. Med. Chem. 58, 116577. doi: 10.1016/j.bmc.2021.116577

Beltran-Hortelano, I., Perez-Silanes, S., and Galiano, S. (2017). Trypanothione reductase and superoxide dismutase as current drug targets for Trypanosoma cruzi.
An overview of compounds with activity against Chagas disease. Curr. Med. Chem. 24 (11), 1066–1086. doi:10.2174/092986717366661227094018

Benaim, G., Pania-Mondolfi, A. E., Sordillo, E. M., and Martinez-Sotillo, N. (2020). Disruption of intracellular calcium homeostasis as a therapeutic target against Trypanosoma cruzi. Front. Cell. Infect. Microbiol. 10, 46. doi:10.3389/fcimb.2020.00064

Bodner, D. L., Dedon, P. C., Keng, P. C., Katz, J. C., and Borch, R. F. (1986) Selective protection against cis-diaminedichloroplatinum(II)-induced toxicity in kidney, gut, and bone marrow by diethyldithiocarbamate Cancer Res. 46 (6), 2751–2755.

Bogacz, M., and Krauth-Siegel, R. L. (2018). Trypanexidin peroxidase-deficiency commits trypanosomes to ferroptosis-type cell death. Elife 7, e37593. doi:10.7554/ elife.37593

Bustamante, J. M., Craft, J. M., Crowe, B. D., Ketchie, S. A., and Tarleton, R. L. (2014). New, combined, and reduced dosing treatments protocols cure Trypanosoma cruzi infection in mice. J. Infect. Dis. 212 (1), 150–162. doi: 10.1093/infdis/jiu240

Campos, M. C. O., Castro-Pinto, D. B., Ribiero, G. A., Berredo-Pinho, M. M., Gomes, I. H. F., da Silva Bellini, M. S., et al. (2013). P-glycoprotein efflux pump plays an important role in Trypanosoma cruzi drug resistance. Parasitology 142 (6), 2341–2351. doi:10.1017/S0031182012001998

Campos, M. C. O., Leon, L. L., Taylor, M. C., and Kelly, J. M. (2014). Benzimidazole-resistance in Trypanosoma cruzi: Evidence that distinct mechanisms can act in concert. Mol. Biochem. Parasitol. 193 (1–3), 17–19. doi:10.1016/j.molbiopara.2014.01.002

Campos, M. C. O., Phelan, J. Francisco, A. F., Taylor, M. C., Lewis, M. D., Pain, A., et al. (2017). Genome-wide mutagenesis and multi-drug resistance in American trypanosomes induced by the front-line drug benzidazole. Sci. Rep. 7 (1), 14407. doi:10.1038/s41598-017-14986-6

Cao, Z., Qin, H., Huang, Y., Zhao, Y., Chen, Z., Hu, J., et al. (2022). Crotalaria spectabilis alkaloids inhibit aldehyde dehydrogenase 2 and 3 and modulate T-cell signaling in Chagas disease. Molecules 27 (9), 3382. doi:10.3390/molecules27093382

Carper, W. R., Dorey, R. C., and Beber, J. H. (1987) Inhibitory effect of disulfiram on alcohol dehydrogenase activity. J. Med. Chem. 30 (10), 1906–1908. doi:10.1021/jm00155a004

Castro, J. A., and Diaz de Toranzo, E. G. (1988). Toxic effects of nifurtimox and benznidazole, two drugs used against American trypanosomiasis (Chagas disease). Int. J. Parasitol. Drugs Drug Resist. 1 (1), 19–25. doi:10.1016/S1567-733X(16)70014-0

Casas, A., et al. (2017). Genome-wide mutagenesis and multi-drug resistance in American trypanosomes induced by the front-line drug benznidazole. Front. Cell. Infect. Microbiol. 7 (3), 301–307.

De Jongh, D. K. (1953a). Effect of tetra-ethylthiuramdisulphide (T.T.S.) on the antimonial activity of quinine in Plasmodium berghei infections in mice. Acta Physiol. Pharmacol. Neerl. 3 (1), 34–37.

De Jongh, D. K. (1953b). Effect of tetra-ethylthiuramdisulphide on the antimonial activity of quinine in Plasmodium galinaceum infections in chickens. Acta Physiol. Pharmacol. Neerl. 3 (1), 38–44.

de Oliveira, T. B., Pedrosa, R. C., and Filho, D. W. (2007). Oxidative stress in chronic cardiopathy associated with Chagas disease. Int. J. Cardiol. 116 (3), 357–363. doi:10.1016/j.ijcard.2006.04.046

Dias, J. C. P., Novaes Ramos, A. Dias Gontijo, E., Lucciotti, A., Sichani Yanaza, M. A., Rodrigues Coura, J., et al. (2016). Il consenso brasileiro in doenca de chaga. Epid. Serv. Saude 25 (21), 1–10. doi:10.5123/S1679-49742016000000002

Dixon, S. J., Lemberg, K. M., Lampricht, M. R., Skouta, R., Zaitsev, E. M., Glasson, C. E., et al. (2012). Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149 (5), 1060–1072. doi:10.1016/j.cell.2012.03.042

Dixon, S. J., Patel, D. N., Welsch, M., Skouta, R., Lee, E. D., Hayano, M., et al. (2014). Pharmacological inhibition of cystine–glutamate exchange induces endoplasmic reticulum stress and ferroptosis. Elife 3, e05253. doi:10.7554/elifescience.org/elifesciences.org/05253

dos Anjos, D. O., Sobral Alves, E. S., Gonçalves, V. T., Fontes, S. S., Nogueira, M. L., Suarez-Fontes, A. M., et al. (2016). Effects of a novel β-lapachone derivative on Trypanosoma cruzi: Parasite death involving apoptosis, autophagy and necrosis. Int. J. Parasitol. Drugs Drug Resist. 6 (3), 207–219. doi:10.1016/j.ipddr.2016.10.003

dos Santos Moura, L., Santana Nunes, V., Gomes, A. S. A., Sousa, A. C. D., de C., Fontes, M. R. M., et al. (2021). Mitochondrial supertox TcSnzr2p3 affects TcSODA activity and oxidative stress response in Trypanosoma cruzi. Front. Cell. Infect. Microbiol. 11, 773410. doi:10.3389/fcimb.2021.773410

Duschak, V. G. (2019). A decade of targets and patented drugs for chemotherapy of Chagas disease. Recent Pat. Anti-Infect. Drug Discov. 6 (3), 216–259. doi:10.2174/1578517X117896887664

Duschak, V. G. (2016). Targets and patented drugs for chemotherapy of Chagas disease in the last 15 years-period. Recent Pat. Anti-Infect. Drug Discov 11 (2), 74–173. doi:10.2174/1578517X117896887664

Engel, J. C., Franke de Cazzulo, B. M., Stoppani, A. O., Cannata, J. J., and Filho, D. W. (2007). Oxidative stress in chronic cardiopathy associated with Chagas disease. Int. J. Cardiol. 116 (3), 357–363. doi:10.1016/j.ijcard.2006.04.046

Ferreira Jr., E. D., Souza, E. M., Ferreira Jr., F. S., Cerba, M. C. O., et al. (2018). Insights of antiparasitic activity of sodium diethyldithiocarbamate against different strains of Trypanosoma cruzi. Parasitology 145 (4), 497. doi:10.1016/j.parasite.2018.03.049

Frontiers in Cellular and Infection Microbiology frontiersin.org)

Frontiers in Cellular and Infection Microbiology frontiersin.org
parasites for domestic transmission. Infect. Genet. Evol. 25, 36–43. doi: 10.1016/j.igene.2014.08.002
Esmaeili, Y., Yarjani, Z., Pakravan, F., Bidram, E., Los, M. J., Esraghi, M., et al. (2022). Targeting autophagy, oxidative stress, and ER stress for neurodegenerative disease treatment. J. Control Release 345, 147–175. doi: 10.1016/j.jconrel.2022.03.035
Fainé, N., López-Mulet, R., Torres, G., Morello, A., Ferreira, J., Kemmerling, U., et al. (2008). Buthionine sulfoxime has anti-Trypanosoma cruzi activity in a murine model of acute Chagas’ disease and enhances the efficacy of nifurtimox. Antimicrob. Agents Chemother. 52 (5), 1837–1839. doi: 10.1128/AAC.01454-07
Fainé, N., Pino, L., Letelier, P., Ortiz, C., López, R., Seguel, C., et al. (2005). Buthionine sulfoxime increases the toxicity of nifurtimox and benznidazole to Trypanosoma cruzi. Antimicrob. Agents Chemother. 49 (1), 126–130. doi: 10.1128/AAC.49.1.126-130.2005
Fivelman, Q. L., Adagu, I. S., and Warhurst, D. C. (2004). Modified fixed-ratio isologous bone marrow chimeras: an approach to generate mice between atoaxogene and proguanil or dihydroartemisinin against drug-resistant strains of Plasmodium falciparum. Antimicrob. Agents Chemother. 48 (11), 4097–4102. doi: 10.1128/AAC.48.11.4097-4102.2004
Franco-Paredes, C., Bortzaxi, M. E., and Hoter, P. J. (2009). The unfinished public health agenda of Chagas disease in the era of globalization. PLoS Negl. Trop. Dis. 3 (7), e740. doi: 10.1371/journal.pntd.0000470
Frisoni, G. B., and Di Monda, V. (1989). Disulfiram nephropathy: a review 1971-1988 and a plea for the use of alcohol metabolites in therapy. Acta. Pharmacol. Toxicol. 64 (2), 249–437.
Gandara, D. R., Wiebe, V. J., Perez, E. A., Makuch, R. W., and DeGregorio, M. W. (1990). Captopil rescue therapy: Experience with sodium thiosulfate, WR2721, and diethyldithiocarbamate. Crit. Rev. Oncol. Hemotol. 10 (4), 353–365. doi: 10.1016/1040-8282(90)90010-P
Gao, M., Ye, Y., Zhu, M., Mihrun, A. M., Monian, P., Thompson, C. B., et al. (2019). Role of mitochondria in ferroptosis. Mol. Cell. 73 (2), 354–363.e3. doi: 10.1016/j.molcel.2018.10.042
García-Hernández, R., Manzano, J. I., and Castanyas S and Gamarro, F. (2012). Leishmania donovani develops resistance to drug combinations. PLoS Negl. Trop. Dis. 6 (12), e1794. doi: 10.1371/journal.pntd.0001794
Gessner, P. K., and Gessner, T. (1992). Disulfiram and its metabolite, diethyldithiocarbamate. Springer Netherlands 452 pp. doi: 10.1007/978-94-011-2328-0
Ghosh, S., Farr, L., Singh, A., Leaton, L. A., Padalia, J., Shirley, D. A., et al. (2020). COP9 signalosome is an essential and drugable parasite target that regulates protein degradation. PLoS Pathog. 16 (9), e1008592. doi: 10.1371/journal.ppat.1008592
Giovalli, C., Turrens, J. F., and Boveris, A. (1988). Chemiluminescence enhanced by 1,2-cyano-2,3-dihydro-1,3-quinodimethane and diethyldithiocarbamate. J. Biol. Chem. 263 (10), 3856–3859.
González-Chávez, Z., Olim-Sandoval, V., Rodríguez-Zavala, J. S., Moreno-Sánchez, R., and Saavedra, E. (2015). Metabolic control analysis of the Trypanosoma cruzi peroxide detoxification pathway identifies trypanox as a suitable drug target. Biochim. Biophys. Acta 1850 (2), 263–273. doi: 10.1016/j.bbadgen.2014.10.029
González-Chávez, Z., Vázquez, C., Mejía-Tlamichi, M., Martínez-Duertas, C., Manning-Cela, R., Encalada, R., et al. (2019). Gamma-glutamylcysteine synthetase inhibits HIV-1 env high control on the antioxidant system in Trypanosoma cruzi contributing to drug resistance and infectivity. Redox Biol. 26, 101231. doi: 10.1016/j.redox.2019.101231
González, L., García-Huertas, P., Triana-Chávez, O., Garcia, G. A., Murta, S. M. F., and Mejía-Jaramillo, A. M. (2017). Aldehyde reductase and alcohol dehydrogenase contribute to benznidazole natural resistance in Trypanosoma cruzi. Mol. Microbiol. 106 (5), 704–711. doi: 111.mmi.13830
Guggenbühl Noller, J. M., Froeschl, G., Eisermann, P., Jochum, J., Theuring, S., Jedlitschky, G., Leier, I., Buchholz, U., Center, M., and Keppler, D. (1994). ATP-dependent transport of glutathione s-conjugates by the multidrug resistance-associated protein. Cancer Res. 54 (18), 4833–4836.
Jia, Y., and Huang, T. (2013). Overview of antabuse® (Disulfiram) in radiation and cancer biology. Cancer Manage. Res. 13, 4095–4101. doi: 10.2147/CMAR.S308168
Jiang, H., Zhao, Y., Tang, H., Duan, S., Li, M., Yang, X., et al. (2021). Tetraethylthiuram disulfide alleviates pulmonary fibrosis through modulating transforming growth factor-β signalling. Pharmacol. Res. 174, 105923. doi: 10.1016/j.phrs.2021.105923
Jin, L., Davis, M. R., Hu, P., and Baillie, T. A. (1994). Identification of novel glutathione conjugates of disulfiram and diethyldithiocarbamate in rat bile by liquid chromatography-tandem mass spectrometry. evidence for metabolic activation of disulfiram in vivo. Chem. Res. Toxicol. 7 (4), 526–533. doi: 10.1021/tx0300840
Kanai, K., Itoh, N., Ito, Y., Nagai, N., Horii, Y., Chikazawa, S., et al. (2011). Anti-inflammatory potency of oral disulfiram compared with desamethasone on endotoxin-induced uvetis in rats. J. Vet. Med. Science. 73 (4), 517–520. doi: 10.1292/jvms.2010.0293
Kang, J., Sun, Y., Deng, Y., Liu, Q., Li, D., Liu, Y., et al. (2020). Autophagy-endoplasmic reticulum stress inhibition mechanism of superoxide dismutase in the formation of calcium oxalate kidney stones. Biomac. Pharmacother. 121, 109649. doi: 10.1016/j.biomac.2019.109649
Kannappan, V., Ali, M., Small, B., Rajendran, G., Elhenni, S., Taj, H., et al. (2021). Recent advances in repurposing disulfiram and disulfiram derivatives as copper-dependent anticancer agents. Front. Mol. Biosci. 8, 741316. doi: 10.3389/fmolb.2021.741316
Khouri, R., Novais, F., Santana, G., de Oliveira, C. I., Vannier dos Santos, M. A., Baral, A., et al. (2010). DETC induces Leishmania parasite killing in human liver and spleen in vivo models: A promising therapeutic alternative in leishmaniasis. PLoS One 5 (12), e14394. doi: 10.1371/journal.pone.0014394
Kim, S. H., Seo, H., Kwon, D., Yud, D. Y., and Jung, Y. S. (2022). Taurine ameliorates tunicamycin-induced liver injury by disrupting the vicious cycle between oxidative stress and endoplasmic reticulum stress. Life 12 (3), 534. doi: 10.3390/life12030354
Kona, F. R., Buc, D., and Burger, A. (2011). Disulfiram, and disulfiram derivatives as novel potential anticancer drugs targeting the ubiquitin proteasome system in both preclinical and clinical studies. Curr. Cancer Drug Targets 11 (3), 338–346. doi: 10.2174/156800911795491978. XXXX
Koto, K. S., Lescalt, P., Brard, L., Kim, K., Singh, R. K., Bond, J., et al. (2011). Antitumor activity of nifurtimox is enhanced with tetrathiomolybdate in medulloblastoma. Int. J. Oncol. 38 (5), 1329–1341. doi: 10.3892/ijot.2011.871
Kyle, M. E., Serroni, A., and Farber, I. L. (1989). The inhibition of lipoperoxidation by disulfiram prevents the killing of cultured hepatocytes by allyl...
alcohol, tert-butyl hydroperoxide, hydrogen peroxide and diethyl maleate. Chem. Biol. Interact. 133, 269–275. doi:10.1016/S0009-2797(03)00003-3

Lane, J. E., Ribeiro-Rodrigues, R., Suarez, C. C., Bogtish, B. J., Jones, M. M., Singh, P. K., et al. (1996). In vitro trypanocidal activity of tetraethyuthiuranil disulfide and sodium diethylamine-n-carboxidithioate on Trypanosoma cruzi. Am. J. Trop. Med. Hyg. 55 (3), 263–266. doi:10.4269/ajtmh.1996.55.263

Lee, R. Y., Bacon, K. M., Bottarelli, M. E., and Hotze, P. J. (2013). Global economic burden of Chagas disease: a computational simulation model. Lancet Infect. Dis. 13 (4), 342–348. doi:10.1016/S1473-3099(13)70002-1

Lehár, J., Krüger, A. S., Avery, W., Heilbut, A. M., Johansen, L. M., Price, E. R., et al. (2009a). Synergistic drug combination treatments to improve therapeutically relevant selectivity. Nat. Biotechnol. 27 (7), 659–666. doi:10.1038/nbt.1549

Lehár, J., Krüger, A. S., Zimmermann, G. R., and Borysi, A. A. (2009b). Therapeutically selective and the multi-node drug target. Discov Med. 8 (34), 185–190.

Levi, G. C., Lobo, I. F., Kallas, E. G., and Amato Neto, V. (1996). Ethological drug treatment of human infection by Trypanosoma cruzi. Rev. Inst. Med. Trop. São Paulo 38 (1), 35–38. doi:10.1016/S0035-4661(96)900007-0

Libeu, C. A. P., Descamps, O., Zhang, J., John, V., and Bredesen, D. E. (2012). Altering APP proteolysis: Increasing sAPPalpha production by targeting dimerization of the APP ectodomain. PloS One 7 (6), e40027. doi:10.1371/journal.pone.0040027

Liu, Y., Tong, Z., Shi, J., Li, R., Upton, M., and Wang, Z. (2021). Drug repurposing for next-generation combination therapies against multidrug-resistant bacteria. Tannicomics 11 (10), 4910–4928. doi:10.1710/scn056205

Liu, X., Zhang, R., Huang, L., Zheng, Z., Vlassara, H., Striker, G., et al. (2019). Excessive oxidative stress contributes to increased acute ER stress kidney injury in aged mice. Oxid. Med. Cell. Longev. 2019, 1–15. doi:10.1155/2019/2745621

Li, N., Wang, Y., Wang, X., Sun, N., and Gong, Y.-H. (2022). Pathway network of pyroptosis and its potential inhibitors in acute kidney injury. Pharmacol. Res. 175, 106033. doi:10.1016/j.phrs.2021.106033

Lee, D. W., Deeye, R. G., and Cole, S. P. (1998). Characterization of vircistatin transport by the Mdr190,000 multidrug resistance protein (MRP): evidence for cotransport with reduced glutathione. Cancer Res. 58 (22), 5130–5136.

Lee, T. W., Bartlett, M. C., and Clarke, D. M. (2000). Blockage of drug resistance by inhibition of osteoblast function due to suppression of acetaldehyde metabolism. J. Cell. Physiol. 185 (1), 61–69. doi:10.1002/1097-0022(200006)185:1<61::AID-JCP1>3.0.CO;2-Q

Lee, T. W., and Clarke, D. M. (1998). Reduced antioxidant capacity and diet-induced atherosclerosis in uncoupling protein-1-deficient mice. J. Biol. Chem. 273 (37), 24101–24106. doi:10.1074/jbc.273.37.24101

Leiner, G. C., Lobo, I. M. F., Kalla, M., Azevedo, J., Neves, O., Assunção, B., et al. (2019). Benznidazole-resistance in Trypanosoma cruzi population with new logos? Cancers 12 (12), 3535. doi:10.3390/cancers12123538

Mees, A. C., Sasoni, N., Arias, D. G., Pérez Brandán, C., Orban, O. C. F., Kunick, C., et al. (2019). Trypanosoma synthetase confers growth, survival advantage and resistance to anti-protozoal drugs in Trypanosoma cruzi. Free. Rad. Biol. Med. 130, 23–34. doi:10.1016/j.freeradbiomed.2018.10.436

Miller, A. C., and Blakely, W. F. (1992). Inhibition of glutathione reductase activity by a carbomoylating nitrosourea: Effect on cellular radiosensitivity. Cancer Res. 52 (1), 666–672. doi:10.1158/0008-5472.CAN-88-0888

Montalbano, R., Waldegger, P., Quint, K., Jabari, S., Neureiter, D., Illig, R., et al. (2013). The thioacetamide disulfide drug, disulfiram induces osteorad in rats by inhibition of osteoblast function due to suppression of acetaldehyde dehydrogenase activity. Toxicol. Sci. 139 (1), 257–269. doi:10.1093/toxsci/kft020

Mohsin, A., Khan, K., Pal, S., Porwal, K., Chima, S. P., Barbhuyan, T. K., et al. (2014). The thioacetamide disulfide drug, disulfiram induces osteorad in rats by inhibition of osteoblast function due to suppression of acetaldehyde dehydrogenase activity. Toxicol. Sci. 139 (1), 257–269. doi:10.1093/toxsci/kft020

Müller, J., and Hemphill, A. (2016). Drug target identification in protozoan parasites. Expert. Opin. Drug Discov 11 (8), 815–824. doi:10.1080/17460954.2016.1195945

Munoz, A. A., Thompson, J., Hu, Y., Holinder, J., Lesniewski, E. J., and Chen, Q. (2020). Endoplasmic reticulum stress-induced complex I defect: Central role of calcium dysregulation as a therapeutic agent for metastatic malignant melanoma—old myth or new logic? Cancers 12 (12), 3535. doi:10.3390/cancers12123538

Musa, J. E., Assunção, B., Chaves, A. C., Sasoni, N., Arias, D. G., Peña, J., et al. (2015). A phase IIb trial assessing the addition of disulphiram to standard chemotherapy in patients with metastatic melanoma. Discov Med. 8 (43), 185–190.

Nagendra, S. N., Shetty, K. T., Rao, K. M., and Bao, S. S. (1994). Effect of disulfiram administration on rat brain glutathione metabolism. Alcohol 11 (1), 7–10. doi:10.1016/0740-5862(94)90004-3

Neal, R. A., and van Bueren, J. (1988). Comparative studies of drug susceptibility of N. americanus and N. brasiliensis from Brazil and the USA. Trans. R. Soc Trop. Med. Hyg. 82 (5), 709–714. doi:10.1093/trstmh/82.5.709

Nechushtan, H., Hamamreh, Y., Nidal, S., Gotfried, M., Baron, A., Shalev, Y. I., et al. (2015). A phase IIb trial assessing the addition of disulfiram to chemotherapy for the treatment of metastatic non-small cell lung cancer. Oncologist 20 (4), 366–372. doi:10.1634/theoncologist.2014-0424

Ningjaraj, N. S., Chen, W., Schloss, J. V., Faiman, M. D., and Wu, J. Y. (2001). S-methyl N,N-diethylthiocarbamate sulfoxide elicits neuroprotective effect against n-methyl-D-aspartate receptor-mediated neurotoxicity. J. Biomed. Sci. 8 (1), 104–113. doi:10.1007/BF02255978

Ningjaraj, N. S., Schloss, J. V., Williams, T. D., and Faiman, M. D. (1998). Glutathione carbamoylation by S-methyl N,N-diethylthiocarbamate sulfoxide and sulfone. Biochem. Pharmacol. 55 (6), 749–756. doi:10.1016/S0006-2952(97)00513-3

Nogueira, F. B., Krieger, M. A., Nirde, A. C., et al. (2012). Benznidazole resistance in Trypanosoma cruzi strains resistant to benznidazole occurring in Colombia. Biomédica 32 (2), 196–205. doi:10.1016/S0747-4523(0800007)

O’Brien, A., Barber, J. B., Reid, S., Niknejad, N., and Dimitrioulopoulos, J. (2012). Enhancement of cisplatin cytotoxicity by disulfiram involves activating transcription factor 3. Anticancer Res. 32 (7), 2679–2688.
Ohno, Y., Hirota, K., Kawanishi, T., and Takanaa, A. (1990). Loss of viability after dilution treatment without preceding depletion of intracellular GSH. J. Toxicol. Sci. 15 (2), 63–73. doi: 10.2131/jts.15.63

Oliveira, M. J., Cucunubá, Z. M., Vilela-Mendes, C. A., Herazo, R., Agreda-Rudenko, D., Florê, C., et al. (2017). Risk factors for treatment interruption and severe adverse effects to benznidazole in adult patients with Chagas disease. PloS One 12 (9), e0183503. doi: 10.1371/journal.pone.0183503

Olm, F., Urbanová, K., Rosales, M. J., Martín-Escalon, R., Sánchez-Moreno, M., and Marín, C. (2015). An in vitro iron superoxide dismutase inhibitor decreases the parasitemia levels of Trypanosoma cruzi in BALB/c mouse model during acute phase. Int. J. Parasitol. Drugs Drug Resist. 5 (3), 110–116. doi: 10.1016/j.ijppdr.2015.05.002

Pales, I., Lara-Ramirez, E. E., Lopez-Cedillo, C. J., Garcia-Perez, C., Kashif, M., Bocanegra-Garcia, V., et al. (2017). Repositioning FDA drugs as potential cruzain inhibitors from the Food and Drug Administration. Frontiers in Cellular and Infection Microbiology frontiersin.org 19

Barbosa, H. S., et al. (2010). Arylhydrazone derivatives of megazol against Trypanosoma cruzi. Chronobiol. Int. 27 (3), 573–587. doi: 10.3109/07420528609083160

Almeida-Silva et al. 10.3389/fcimb.2022.926699

Sauna, Z. E., Peng, X.-H., Nandigama, K., Tekle, S., and Ambakud, S. V. (2004). The molecular basis of the action of disulfiram as a modulator of the multidrug resistance-linked ATP binding cassette transporters MDR1 (ABCB1) and MRPI (ABCC1). Mol. Pharmacol. 65 (3), 675–684. doi: 10.1124/mol.65.3.675

Shmidtova, S., Kalavka, K., Gercelova, K., Cunza, Z., Målklona, S., Snellova, B., et al. (2019). Disulfiram overcomes ciplistin resistance in human embryonal carcinoma cells. Cancers 11 (9), 1224. doi: 10.3390/cancers11091224

Sellar, J., and Lindsay, R. H. (1968). Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with eillman’s reagent. Anal. Biochem. 25, 192–205. doi: 10.1016/0003-2697(68)90092-4

Shah O’Brien, P., Xi, Y., Miller, J. R., Brownell, A. L., Zeng, Q., Yoo, G. H., et al. (2019). Disulfiram (Antabuse) activates ROS-dependent ER stress and apoptosis in oral cavity squamous cell carcinoma. J. Clin. Med. 8 (5), 611. doi: 10.3390/jcm8050614

Sinar, J., M. A., Chambers, S. E., Shiles, C. J., and Baldwin, D. S. (2016). Safety and tolerability of pharmacological treatment of alcohol dependence: comprehensive review of evidence. Drug Saf. 39 (7), 627–645. doi: 10.1007/s12241-016-0146-y

Soares, C. O., Coli, W., Bechara, E. J. H., and Abves, M. J. (2012). 1,4-Diamino-2-butanone, a putrescine analogue, promotes redox imbalance in Trypanosoma cruzi and mammalian cells. Arch. Biochem. Biophys. 528 (2), 103–109. doi: 10.1016/j.abb.2012.08.042

Soares, C., Viola-Renals, M., Elphou, Y. K., Peng, T., and Doz, P. (2014). Repositioning an old anti-alcoholism drug. disulfiram as a selective, effective and economical anticancer agent. J. Dev. Drugs 05 (02), 1000147. doi: 10.4172/2329-6631.1000147

Soares, C., Viola-Renals, M., Olindo, M. D., Shinde, S. D., Chatterjee, S., Chaudhari, S. S., Bhangle, H. A., et al. (2018). A chemosensitizer drug: disulfiram prevents doxorubicin-induced cardiac dysfunction and oxidative stress in rats. Cardiovasc. Toxicol. 18 (5), 459–470. doi: 10.1007/s12012-018-9458-y

Stockwell, B. R., Friedmann Angeli, J. P., Bayrù, H., Bush, A. I., Conrad, M., Dixon, S. J., et al. (2017). Ferropot: A regulated cell death nexus linking metabolism, redox biology, and disease. Cell 171 (2), 273–285. doi: 10.1016/j.cell.2017.09.021

Stromme, J. H. (1963). Effects of diethyldithiocarbamate and disulfiram on glucose metabolism and glutathione content of human erythrocytes. Biochem. Pharmacol. 12 (7), 705–715. doi: 10.1016/0003-2697(68)90086-7

Suëth-Santiago, V., Morais, J. B., Sobral Alves, E. S., Vannier-Santos, M. A., Freire-de-Lima, C. G., Castro, R. N., et al. (2016). The effectiveness of natural diethylthiocarbamates against Trypanosoma cruzi: cytotoxicity, ultrastructural alterations and molecular modeling studies. PloS One 11 (9), e0162926. doi: 10.1371/journal.pone.0162926

Sun, W., Sanderson, P. E., and Zheng, W. (2016). Drug combination therapy increases successful drug repositioning. Drug Discov Today 21 (7), 1189–1195. doi: 10.1016/j.drudis.2016.05.015

Sun, S., Shi, G., Han, X., Francisco, A. B., Ji, Y., Mendonça, N., et al. (2014). Sel1l is indispensable for mammalian endosomal reticulum-associated degradation, endosomal reticulum homostasis, and survival. Proc. Natl. Acad. Sci. U.S.A. 111 (5), E582–E591. doi: 10.1073/pnas.1318141111

Talaván, A., and Teixeira, M. M. (2011). Inflammation and Chagas disease. Adv. Parasitol. 76, 171–194. doi: 10.1016/S0065-277X(11)60008-6

Teston, A. P. M., Monteiro, W. M., Reis, D., Bossolani, G. D. P., Gomes, M. L., de Araújo, S. M., et al. (2013). In vivo susceptibility to benznidazole of Trypanosoma cruzi strains from the Western Brazilian Amazon. Trop. Med. Infect. Dis. 18 (1), 111. doi: 10.2131/jts.121014

Tonkin, E. G., Valentine, H. L., Milutovic, D. M., and Valentine, W. M. (2004). N,N-diethyldithiocarbamate produces copper accumulation, lipid peroxidation, and myelin injury in rat peripheral nerve. Toxicol. Sci. 81 (1), 160–171. doi: 10.1093/toxsci/kdh190

Valentine, H. L., Viquez, O. M., Amarnath, K., Amarnath, V., Zyskowsk, J., Kassa, E. N., et al. (2009). Nitrogen substituent polarity in diethyldithiocarbamate-mediated lipid oxidation, nerve copper accumulation, and myelin injury. Chem. Res. Toxicol. 22 (1), 218–226. doi: 10.1021/tx8003714

Vannier-Santos, M. A., and De Castro, S. (2009). Electron microscopy in antiparasitic chemotherapy: a (close) view to a kill. Curr. Drug Targets 10 (3), 246–260. doi: 10.2174/13894500978511168

Vannier-Santos, M. A., and Lima, L. (2001). Cytotoxic techniques and energy-filtering transmission electron microscopy applied to the study of parasitic protozoa. Biol. Proced. Online 3, 8–18. doi: 10.1251/bpo19

Vannier-Santos, M. A., Menezes, D., Oliveira, M. F., and de Mello, F. G. (2008). The putrescine analogue 1,4-diamino-2-butanone affects polyamine synthesis, transport, ultrastructure and intracellular survival in Leishmania amazonensis. Microbiol. 154 (10), 3104–3111. doi: 10.1099/mic.0.2007/013896-0
Vannier-Santos, M. A., and Suarez-Fontes, A. M. (2017). Role of polyamines in parasite cell architecture and function. *Curr. Pharm. Des.* 23 (23), 3342–3358. doi: 10.2174/13816128236661703163458

Vázquez, C., Mejía-Tlachi, M., González-Chávez, Z., Silva, A., Rodríguez-Zavala, J. S., Moreno-Sánchez, R., et al. (2017). Buthionine sulfoximine is a multitarget inhibitor of trypanothione synthesis in *Trypanosoma cruzi*. *FEBS Lett.* 591 (23), 3881–3894. doi: 10.1016/j.febslet.2017.04.12904

Vazquez, O. M., Lai, B., Ahn, J. H., Does, M. D., Valentine, H. L., and Valentine, W. M. (2009). N,N-diethyldithiocarbamate promotes oxidative stress prior to myelin structural changes and increases myelin copper content. *Toxicol. Appl. Pharmacol.* 239 (1), 71–79. doi: 10.1016/j.taap.2009.05.017

Waghabi, M. C., Ferreira, R. R., Abreu, R., da, S., Degrave, W., de Souza, E. M., et al. (2022). Transforming growth factor-ß as a therapeutic target for the cardiac damage of Chagas disease. *Mem. Inst. Oswaldo Cruz.* 117, e210395. doi: 10.1590/0074-02760210395

Wang, J., Yang, X., and Zhang, J. (2016). Bridges between mitochondrial oxidative stress, ER stress and mTOR signaling in pancreatic β cells. *Cell. Signal.* 28 (8), 1099–1104. doi: 10.1016/j.cellsig.2016.05.007

Wei, S., Xiao, Z., Huang, J., Peng, Z., Zhang, B., and Li, W. (2022). Disulfiram inhibits oxidative stress and NLRP3 inflammasome activation to prevent LPS-induced cardiac injury. *Int. Immunopharmacol.* 105, 108545. doi: 10.1016/j.intimp.2022.108545

Wertz, I. E., and Wang, X. (2019). From Discov to bedside: targeting the ubiquitin when the whole is greater than the sum of the parts. *Drug Discov Today* 23 (11), 903–914. doi: 10.1016/j.drudis.2019.02.001

Yamada, Y., Enokida, H., Osako, Y., Tsuruda, M., Kuroshima, K., et al. (2020). Targeting NPL4 via drug repositioning using disulfiram for the treatment of clear cell renal carcinoma. *PloS One* 15 (7), e0236119. doi: 10.1371/journal.pone.0236119

Yoshino, H., Yamaeda, Y., Enokida, H., Osako, Y., Tsuruda, M., Kuroshima, K., et al. (2020). Targeting NPL4 via drug repositioning using disulfiram for the treatment of clear cell renal carcinoma. *PloS One* 15 (7), e0236119. doi: 10.1371/journal.pone.0236119

Zhang, Y., Zhang, R., and Han, X. (2021). Disulfiram inhibits inflammation and fibrosis in a rat unilateral ureteral obstruction model by inhibiting gasdermin d cleavage and pyroptosis. *Inflamm. Res.* 70 (5), 543–552. doi: 10.1007/s00011-021-01457-y

Zhao, A., Wu, Z.-Q., Pollack, M., Rollwagen, F. M., Hirsael, P., and Zhou, X. (2000). Disulfiram inhibits TNF-alpha-induced cell death. *Cytokine* 12 (9), 1356–1367. doi: 10.1006/cyto.2000.0725

Zheng, W., Sun, W., and Simeonov, A. (2018). Drug repurposing screens and synergistic drug-combinations for infectious diseases. *Br. J. Pharmacol.* 175 (2), 181–191. doi: 10.1111/bph.13895

Zhou, Q., Wang, W., Yang, F., Wang, H., Zhao, X., Zhou, Y., et al. (2022). Disulfiram suppressed pertussis fibrosis through inhibiting macrophage accumulation and its pro-inflammatory properties in tendon bone healing. *Front. Biosci. Bioltechnol.* 10, 821933. doi: 10.3389/fbioe.2022.821933

Zimmermann, G. R., Lehár, J., and Keith, C. T. (2007). Multi-target therapeutic when the whole is greater than the sum of the parts. *Drug Discov Today* 12 (1–2), 34–42. doi: 10.1016/j.drudis.2006.11.008

Zingales, B. (2018). *Trypanosoma cruzi* genetic diversity: Something new for something known about Chagas disease manifestations, serodiagnosis and drug sensitivity. *Acta Trop.* 184, 38–52. doi: 10.1016/j.actatropica.2017.09.017

Zingales, B., Araujo, R. G. A., Moreno, M., Franco, J., Aguiar, P. H. N., Nunes, S. L., et al. (2015). A novel ABCG-like transporter of *Trypanosoma cruzi* is involved in natural resistance to benzimidazole. *Mem. Inst. Oswaldo Cruz.* 110 (3), 433–444. doi: 10.1590/0074-02760140407